<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B01D4CE2-0A2F-46F4-AEBE-2AAF28293D97"><gtr:id>B01D4CE2-0A2F-46F4-AEBE-2AAF28293D97</gtr:id><gtr:name>European Lead Factory</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Clinical Science at South Bristol</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B01D4CE2-0A2F-46F4-AEBE-2AAF28293D97"><gtr:id>B01D4CE2-0A2F-46F4-AEBE-2AAF28293D97</gtr:id><gtr:name>European Lead Factory</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/656AE7EB-E856-4F25-A874-9857FE95083C"><gtr:id>656AE7EB-E856-4F25-A874-9857FE95083C</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Wynick</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000863"><gtr:id>7A09CAAB-97BC-477F-B6B1-9E761AB3F944</gtr:id><gtr:title>Use of the tetracycline-regulated transactivator system to study the role played by galanin in sensory neuron survival</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000863</gtr:grantReference><gtr:abstractText>Galanin is a small protein that is widely expressed in the pain-sensing nerves (DRG) of the body. The levels of galanin in these nerves increase by a least 100 fold after an injury or cut to the nervous system. To find out more about the galanin protein we have used the techniques of genetic engineering to generate mice in which galanin has been deleted in the pain sensing nerves. This causes a complete reversal of neuropathic pain in a number of different animal models. We have now shown that galanin is necessary for the survival of some pain sensing neurons and in its absence they die shortly after birth.

This application is a direct continuation of our previous MRC-funded studies and we will use the latest techniques in genetic engineering to separate and further study the roles played by galanin and its receptor subtypes in the pain sensing nerves during development and in the adult, with specific reference to neuropathic pain behaviour.</gtr:abstractText><gtr:technicalSummary>One of the most potent changes observed in the dorsal root ganglion (DRG) following injury, is the 120-fold increase in the levels of the neuropeptide galanin. Work undertaken during my MRC Clinician Scientist Fellowship, Career Establishment Grant and Programme Grant has demonstrated that knockout of the neuropeptide galanin or its receptor GalR2 causes the developmental loss of a subset of pain sensing neurons (nociceptors) in the early postnatal period. This neuronal loss underlies the complete absence of neuropathic pain (NP) observed in both KO mice. 

We have used the tetracycline-regulated transactivator system to inducibly rescue the existing GalKO allowing us to separate and independently study the developmental survival and adult trophic roles played by galanin. We will use these novel transgenic lines to address the following aims:- 

(1) Identify the time course and mechanisms by which galanin and GalR2 play a developmental survival role to a subset of nociceptors and how the neuropeptide interacts with other known neurotrophic factors. 
(2) Define the phenotype of the nociceptors that are lost in the early post-natal period. 
(3) Study how the presence or absence of developmental deficits modifies NP, without the confounding effects of the absence of galanin in the adult. 
(4) Identify and then functionally characterise the genes whose expression is altered in the DRG of adult Gal-KO and GalR2-KO animals by the developmental loss of a subset of nociceptors.</gtr:technicalSummary><gtr:fund><gtr:end>2013-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>701358</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Technology (MRCT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRCT Centre for Therapeutics Discovery (CTD)</gtr:department><gtr:description>identification of novel peptidomimetics for GalR2</gtr:description><gtr:id>5DEEB246-A00F-4DDF-BA3E-0FF0BE61A9E2</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>EirACTdpArz-1</gtr:outcomeId><gtr:partnerContribution>resources to undertake the HTS and subsequent assays</gtr:partnerContribution><gtr:piContribution>I initiated the collaboration and have worked very closely with the MRCT team to initiate and conduct the screen</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Lead Factory</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>HTS for GalR2 PAMs</gtr:description><gtr:id>231A6343-27A3-4426-9765-29309D6D4CDB</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>5881d727e8d745.71735466-1</gtr:outcomeId><gtr:partnerContribution>they funded the screen</gtr:partnerContribution><gtr:piContribution>HTS screen for GalR2 PAMs</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>AAB website</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>027D7304-D2FC-4ACC-92A6-7BF3C1C54A29</gtr:id><gtr:impact>I co-founded and run the ask a biology website. See http://www.askabiologist.org.uk/punbb/index.php

lots of interested and enthused children!</gtr:impact><gtr:outcomeId>A745A1F0E0E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>talked at a number of schools in Bristol</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DAC52956-A196-4B59-8BA0-D64D3216F8B2</gtr:id><gtr:impact>various lectures on biology, medicine and neuroscience

lots of interested and enthused children!</gtr:impact><gtr:outcomeId>5FB5F852ED3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>185000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The role of galanin and its receptors in painful diabetic neuropathy</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>Diabetes UK</gtr:fundingOrg><gtr:id>AE388FF4-CCD9-4C31-AB88-AA1999CB749D</gtr:id><gtr:outcomeId>HxRjNy9Ek6L</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>I cretaed a large numbre of galanin Tg mice which I am busy distributing to other academics worldwide who need them for their research</gtr:description><gtr:id>B8C69596-C0FF-4F58-B33A-176DAF349846</gtr:id><gtr:impact>lots of collaborative publications</gtr:impact><gtr:outcomeId>52A6B418A53</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>transgenic mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D9D6ABC5-828D-4F86-AD0F-AE0CE262FE82</gtr:id><gtr:title>Galanin negatively modulates opiate withdrawal via galanin receptor 1.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e49db911f8b211f3ca370d5b913b26d"><gtr:id>9e49db911f8b211f3ca370d5b913b26d</gtr:id><gtr:otherNames>Holmes FE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>aTRW3xENbfU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EE37DF7-050A-4B9F-A54A-A4156A15BD0B</gtr:id><gtr:title>Galanin stimulates neurite outgrowth from sensory neurons by inhibition of Cdc42 and Rho GTPases and activation of cofilin.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e272bfeea2cbc25fa73d3db2ddeeb5ae"><gtr:id>e272bfeea2cbc25fa73d3db2ddeeb5ae</gtr:id><gtr:otherNames>Hobson SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>54044eb43d0153.53028173</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7185A0D2-AD30-4CE7-AE41-12E8AFAC648A</gtr:id><gtr:title>Galanin promotes neuronal differentiation from neural progenitor cells in vitro and contributes to the generation of new olfactory neurons in the adult mouse brain.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66d5d1a454825ac9a2bd44591f47dc7c"><gtr:id>66d5d1a454825ac9a2bd44591f47dc7c</gtr:id><gtr:otherNames>Cordero-Llana O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>54044af60867f7.10466228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC8486CD-3E29-4B02-B52F-0068E9CE82F0</gtr:id><gtr:title>Characterisation of the nociceptive phenotype of suppressible galanin overexpressing transgenic mice.</gtr:title><gtr:parentPublicationTitle>Molecular pain</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b484cd6cacf619be86308ab2809c214"><gtr:id>6b484cd6cacf619be86308ab2809c214</gtr:id><gtr:otherNames>Pope RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1744-8069</gtr:issn><gtr:outcomeId>dWjvzPuLCWF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA5F7B7A-2F5A-44B4-BA67-359419DC51DC</gtr:id><gtr:title>Galanin-expression and galanin-dependent sensory neurons are not required for itch.</gtr:title><gtr:parentPublicationTitle>Molecular pain</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e49db911f8b211f3ca370d5b913b26d"><gtr:id>9e49db911f8b211f3ca370d5b913b26d</gtr:id><gtr:otherNames>Holmes FE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1744-8069</gtr:issn><gtr:outcomeId>54044eb3df0b30.77508063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96EF234B-BD94-4671-A693-9DA72C3FEC03</gtr:id><gtr:title>The role of physical activity and psychological coping strategies in the management of painful diabetic neuropathy--A systematic review of the literature.</gtr:title><gtr:parentPublicationTitle>Physiotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39805b81c63c9d4885e43efb917b3d25"><gtr:id>39805b81c63c9d4885e43efb917b3d25</gtr:id><gtr:otherNames>Davies B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0031-9406</gtr:issn><gtr:outcomeId>56ac724e4db7a5.83592437</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE45CEC9-29F9-466B-8E90-C8A84C7D98F5</gtr:id><gtr:title>Axotomy-induced miR-21 promotes axon growth in adult dorsal root ganglion neurons.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02d1a9a49a5aec691248f7a71f02dff4"><gtr:id>02d1a9a49a5aec691248f7a71f02dff4</gtr:id><gtr:otherNames>Strickland IT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>YWu39B16qYR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BBDC6D1-EFBA-4BDD-807F-61C622B75F31</gtr:id><gtr:title>Effect of neocortical and hippocampal amyloid deposition upon galaninergic and cholinergic neurites in A?PPswe/PS1?E9 mice.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6846a33b17b67194c3454ab8c98f3f04"><gtr:id>6846a33b17b67194c3454ab8c98f3f04</gtr:id><gtr:otherNames>Kelley CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn><gtr:outcomeId>LtisrNmgXTo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F03A120-8CE7-449D-BB01-6897E08A20FD</gtr:id><gtr:title>Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity.</gtr:title><gtr:parentPublicationTitle>Pharmacological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e7d942b874d301c61a08e896158099a"><gtr:id>0e7d942b874d301c61a08e896158099a</gtr:id><gtr:otherNames>Lang R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0031-6997</gtr:issn><gtr:outcomeId>56ac724ea7fc91.61060100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF4E2ECB-745A-4CB9-9436-8244D76846C5</gtr:id><gtr:title>Targeted disruption of the orphan receptor Gpr151 does not alter pain-related behaviour despite a strong induction in dorsal root ganglion expression in a model of neuropathic pain.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e49db911f8b211f3ca370d5b913b26d"><gtr:id>9e49db911f8b211f3ca370d5b913b26d</gtr:id><gtr:otherNames>Holmes FE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn><gtr:outcomeId>5881d5a98710d0.20825553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1565C7D0-3EA7-49D0-9E3B-674F05E8892E</gtr:id><gtr:title>Activation of the galanin receptor 2 in the periphery reverses nerve injury-induced allodynia.</gtr:title><gtr:parentPublicationTitle>Molecular pain</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8779a1576b6dd1d616701d6dea8e4339"><gtr:id>8779a1576b6dd1d616701d6dea8e4339</gtr:id><gtr:otherNames>Hulse RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1744-8069</gtr:issn><gtr:outcomeId>kyq6TNGwsx4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6668915C-E273-4B7B-A20A-ED46183355D9</gtr:id><gtr:title>Galanin is an autocrine myelin and oligodendrocyte trophic signal induced by leukemia inhibitory factor.</gtr:title><gtr:parentPublicationTitle>Glia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/849661f65f34125e5db77dc9b95c7d66"><gtr:id>849661f65f34125e5db77dc9b95c7d66</gtr:id><gtr:otherNames>Gresle MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0894-1491</gtr:issn><gtr:outcomeId>56ac724ecd1da1.52088794</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3426552B-16DF-4E57-A227-455DC053C6ED</gtr:id><gtr:title>The generation of knock-in mice expressing fluorescently tagged galanin receptors 1 and 2.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183c5071f958631cfad60b14adb9026a"><gtr:id>183c5071f958631cfad60b14adb9026a</gtr:id><gtr:otherNames>Kerr N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn><gtr:outcomeId>56ac724e797785.26212981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD6B9DA6-8C38-4175-9D5E-91ED4C7A0B80</gtr:id><gtr:title>VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23697e55e02fdccdb74b54cae1dd7802"><gtr:id>23697e55e02fdccdb74b54cae1dd7802</gtr:id><gtr:otherNames>Beazley-Long N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>54044af6503352.07084728</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>145037FF-E7A4-4C35-B095-9086AF98B38B</gtr:id><gtr:title>Differential roles of galanin on mechanical and cooling responses at the primary afferent nociceptor.</gtr:title><gtr:parentPublicationTitle>Molecular pain</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8779a1576b6dd1d616701d6dea8e4339"><gtr:id>8779a1576b6dd1d616701d6dea8e4339</gtr:id><gtr:otherNames>Hulse RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1744-8069</gtr:issn><gtr:outcomeId>pm_12410_20_22672616</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71797957-D18E-4946-89B5-5953D9C3266B</gtr:id><gtr:title>Endogenous galanin protects mouse hippocampal neurons against amyloid toxicity in vitro via activation of galanin receptor-2.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01a5bd500504437df9469f5b7ab1e953"><gtr:id>01a5bd500504437df9469f5b7ab1e953</gtr:id><gtr:otherNames>Elliott-Hunt CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn><gtr:outcomeId>JcKEp72Fiu1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A4EF264-F04C-46AF-9FD6-C7F28BF3B84D</gtr:id><gtr:title>Evaluating the role of a galanin enhancer genotype on a range of metabolic, depressive and addictive phenotypes.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e93a89334f9c50550bc48b84c0467cb"><gtr:id>7e93a89334f9c50550bc48b84c0467cb</gtr:id><gtr:otherNames>Richardson TG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1552-4841</gtr:issn><gtr:outcomeId>56ac72830ac068.28333875</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000863</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>